Back to Search Start Over

Hyperthyroidism.

Authors :
Chaker L
Cooper DS
Walsh JP
Peeters RP
Source :
Lancet (London, England) [Lancet] 2024 Feb 24; Vol. 403 (10428), pp. 768-780. Date of Electronic Publication: 2024 Jan 23.
Publication Year :
2024

Abstract

Thyrotoxicosis causes a variety of symptoms and adverse health outcomes. Hyperthyroidism refers to increased thyroid hormone synthesis and secretion, most commonly from Graves' disease or toxic nodular goitre, whereas thyroiditis (typically autoimmune, viral, or drug induced) causes thyrotoxicosis without hyperthyroidism. The diagnosis is based on suppressed serum concentrations of thyroid-stimulating hormone (TSH), accompanied by free thyroxine and total or free tri-iodothyronine concentrations, which are raised (overt hyperthyroidism) or within range (subclinical hyperthyroidism). The underlying cause is determined by clinical assessment, detection of TSH-receptor antibodies and, if necessary, radionuclide thyroid scintigraphy. Treatment options for hyperthyroidism include antithyroid drugs, radioactive iodine, and thyroidectomy, whereas thyroiditis is managed symptomatically or with glucocorticoid therapy. In Graves' disease, first-line treatment is a 12-18-month course of antithyroid drugs, whereas for goitre, radioactive iodine or surgery are preferred for toxic nodules or goitres. Evidence also supports long-term treatment with antithyroid drugs as an option for patients with Graves' disease and toxic nodular goitre.<br />Competing Interests: Declaration of interests We declare no competing interests.<br /> (Copyright © 2024 Elsevier Ltd. All rights reserved.)

Details

Language :
English
ISSN :
1474-547X
Volume :
403
Issue :
10428
Database :
MEDLINE
Journal :
Lancet (London, England)
Publication Type :
Academic Journal
Accession number :
38278171
Full Text :
https://doi.org/10.1016/S0140-6736(23)02016-0